FiercePharma

Drug Delivery to the Brain: Engineering Precision Across Novel Modalities

Neurodegenerative diseases such as Alzheimer’s disease (AD), Parkinson’s disease (PD), motor neuron disease (MND, including amyotrophic lateral sclerosis, (ALS)), and frontotemporal dementia (FTD) ...
The Enterprise

As New Drug Modalities Advance, WuXi AppTec Expands Global Capabilities for Peptides, Oligonucleotides and TPDs

SHANGHAI, SHANGHAI, CHINA, June 11, 2026 /EINPresswire.com/ — The rapid rise of new therapeutic modalities — from peptides and oligonucleotides to targeted ...
Labiotech.eu

How macrocyclic drugs are gaining momentum in the cardiometabolic disease space

Discover biotech and big pharma’s emerging interest in developing macrocyclic drugs for cardiometabolic diseases.
markets.financialcontent

insitro to Acquire CombinAbleAI to Complete its Full Stack, Modality-Agnostic AI Platform for Drug Discovery and Design

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness. TherML™ integrates CombinAbleAI’s advanced, next ...
Morningstar%2c Inc.

Ingenix Raises €13m From Sofinnova Partners-Led Syndicate to Scale Modality Fusion, a Novel Architecture for Drug Development

Ingenix's Biological Reasoning Engine fuses biological data through Modality Fusion, a new architecture for AI in drug development. In a recent oncology engagement, the Biological Reasoning Engine ...